E-DRUG: Independent Drug and Healthcare Newsletter for April 2018
------------------------------------------------------------------------------------
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
Newsletter, April 2018
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW Treating intermittent claudication: first encourage patients to follow a walking exercise programme
Some patients with lower limb peripheral artery disease experience pain while walking, due to a reduced ability to increase arterial circulation. What is the harm-benefit balance of treatments aimed at improving their walking capacity?
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the April issue of Prescrire International: Towards better patient care - drugs to avoid in 2018
Prescrire's annual review of drugs to avoid covers all the drugs examined by Prescrire between 2010 and 2017 that are authorised in the European Union or in France. We identified 90 drugs that are more harmful than beneficial in all the indications for which they have been authorised.
Read more
--------------------------------------------------------------------------------
Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients
The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic advance in the treatment of hepatitis C, especially in patients infected by a genotype 2 virus. But the uncertainty surrounding its adverse effects is unacceptable.
Read more
--------------------------------------------------------------------------------
New drugs and indications in 2017: numerous innovations offering no progress
Marketing authorisations often granted too hastily: patients are exposed to medicines with uncertain harm-benefit balances.
Read more
--------------------------------------------------------------------------------
Prescrire's ratings of new products and indications over the past 10 years
Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.
Read more
Share this with a friend or colleague: Forward this email
Get this from a friend? Sign up here
Prescrire International <international@prescrire.org>